Investors seeking to outperform the market often focus on hand-picking stocks. Selecting the right ones has proven to be a key factor in boosting wealth.
The price of Janux Therapeutics Inc (NASDAQ: JANX) closed at $30.12 in the last session, down -2.30% from day before closing price of $30.83. In other words, the price has decreased by -$2.30 from its previous closing price. On the day, 0.61 million shares were traded. JANX stock price reached its highest trading level at $31.0225 during the session, while it also had its lowest trading level at $29.37.
Ratios:
We take a closer look at JANX’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 59.21 and its Current Ratio is at 59.21. In the meantime, Its Debt-to-Equity ratio is 0.02 whereas as Long-Term Debt/Eq ratio is at 0.02.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, H.C. Wainwright on December 03, 2024, Reiterated its Buy rating but revised its target price to $70 from $63 previously.
On December 03, 2024, BTIG Research reiterated its Buy rating and also lowered its target price recommendation from $82 to $100.
On November 22, 2024, Leerink Partners started tracking the stock assigning a Outperform rating and target price of $79.Leerink Partners initiated its Outperform rating on November 22, 2024, with a $79 target price.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Mar 06 ’25 when RA CAPITAL MANAGEMENT, L.P. bought 372,093 shares for $30.78 per share. The transaction valued at 11,453,023 led to the insider holds 10,031,081 shares of the business.
RA CAPITAL MANAGEMENT, L.P. bought 341,742 shares of JANX for $10,471,352 on Mar 05 ’25. The Director now owns 9,658,988 shares after completing the transaction at $30.64 per share. On Mar 07 ’25, another insider, RA CAPITAL MANAGEMENT, L.P., who serves as the Director of the company, bought 110,206 shares for $31.02 each. As a result, the insider paid 3,418,590 and bolstered with 10,141,287 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, JANX now has a Market Capitalization of 1822211840 and an Enterprise Value of 778099008. For the stock, the TTM Price-to-Sale (P/S) ratio is 168.11 while its Price-to-Book (P/B) ratio in mrq is 1.74. Its current Enterprise Value per Revenue stands at 73.489 whereas that against EBITDA is -8.039.
Stock Price History:
The Beta on a monthly basis for JANX is 3.24, which has changed by -0.18697256 over the last 52 weeks, in comparison to a change of 0.10063088 over the same period for the S&P500. Over the past 52 weeks, JANX has reached a high of $71.71, while it has fallen to a 52-week low of $28.92. The 50-Day Moving Average of the stock is -17.01%, while the 200-Day Moving Average is calculated to be -32.85%.
Shares Statistics:
According to the various share statistics, JANX traded on average about 955.79K shares per day over the past 3-months and 709770 shares per day over the past 10 days. A total of 59.06M shares are outstanding, with a floating share count of 49.57M. Insiders hold about 16.13% of the company’s shares, while institutions hold 107.90% stake in the company. Shares short for JANX as of 1741910400 were 10497950 with a Short Ratio of 10.98, compared to 1739491200 on 9091177. Therefore, it implies a Short% of Shares Outstanding of 10497950 and a Short% of Float of 31.5.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
